Semi-automated on-demand control of individual droplets with a sample application to a drug screening assay

Lab on a Chip ◽  
2019 ◽  
Vol 19 (8) ◽  
pp. 1490-1501 ◽  
Author(s):  
Marie Hébert ◽  
Matthew Courtney ◽  
Carolyn L. Ren
Keyword(s):  
Drug Screening ◽  
User Involvement ◽  
High Accuracy ◽  
Microfluidic Channels ◽  
Screening Assay ◽  
Automated Control ◽  
On Demand ◽  
Sample Application ◽  
Drug Screening Assay ◽  
Demand Control

Automated control of individual droplets in microfluidic channels offers tremendous potential for applications requiring high accuracy and minimal user involvement.

scholarly journals Microengineered peripheral nerve-on-a-chip for preclinical physiological testing

Lab on a Chip ◽  
2015 ◽  
Vol 15 (10) ◽  
pp. 2221-2232 ◽  
Author(s):  
Renee M. Huval ◽  
Oliver H. Miller ◽  
J. Lowry Curley ◽  
Yuwei Fan ◽  
Benjamin J. Hall ◽  
...  
Keyword(s):  
Peripheral Nerve ◽  
Drug Screening ◽  
Late Stage ◽  
Nerve Tissue ◽  
Physiological Measures ◽  
Screening Assay ◽  
Lead Compounds ◽  
Drug Screening Assay

A microscale, organotypicin vitromodel of sensory peripheral nerve tissue may be assessed with clinically-relevant morphological and physiological measures for use as a drug screening assay for selecting promising lead compounds with higher chances of late-stage success.

scholarly journals A drug screening assay on cancer cells chronically adapted to acidosis

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Paola Pellegrini ◽  
Jason T. Serviss ◽  
Thomas Lundbäck ◽  
Nicolo Bancaro ◽  
Magdalena Mazurkiewicz ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Drug Screening ◽  
Screening Assay ◽  
Drug Screening Assay

scholarly journals Functional Drug Screening Assay Reveals Potential Glioma Therapeutics

2011 ◽  
Vol 9 (3) ◽  
pp. 281-289 ◽  
Author(s):  
Christian E. Badr ◽  
Thomas Wurdinger ◽  
Bakhos A. Tannous
Keyword(s):  
Drug Screening ◽  
Screening Assay ◽  
Drug Screening Assay

scholarly journals Pharmacological Profile of Brain-derived Neurotrophic Factor (BDNF) Splice Variant Translation Using a Novel Drug Screening Assay

2014 ◽  
Vol 289 (40) ◽  
pp. 27702-27713 ◽  
Author(s):  
Valentina Vaghi ◽  
Alessio Polacchini ◽  
Gabriele Baj ◽  
Vera L. M. Pinheiro ◽  
Annalisa Vicario ◽  
...  
Keyword(s):  
Drug Screening ◽  
Neurotrophic Factor ◽  
Splice Variant ◽  
Brain Derived Neurotrophic Factor ◽  
Pharmacological Profile ◽  
Screening Assay ◽  
Drug Screening Assay ◽  
Novel Drug

A Novel Multiplex Drug Screening Assay for Identification of Potential Compounds with Anti-Myeloma Activity from a Library of 1120 Drugs.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3403-3403
Author(s):  
Rentian Feng ◽  
Anna Lokshin ◽  
Elieser Gorelik ◽  
Suzanne Lentzsch
Keyword(s):  
Multiple Myeloma ◽  
Growth Factors ◽  
Drug Screening ◽  
Myeloma Cell ◽  
Screening Assay ◽  
Drug Screening Assay ◽  
Rpmi 8226 ◽  
Stimulation Of

Abstract The majority of drug screening assays are aimed at selection of compounds that affect proliferation or survival of myeloma cells. However, this approach might fail to identify compounds with a potent therapeutic activity that are unable to directly inhibit tumor cell proliferation in vitro but might have potent anti-tumor activity in vivo by targeting the microenvironment of the myeloma cell. For this purpose we used a Multiplex drug-screening assay (MDSA) to identify compounds with potential anti-myeloma activity from a library of 1120 compounds provided by the Multiple Myeloma Research Foundation (MMRF). MDSA is based on use of the Luminex technology (LabMAP Multianalyte Profiling), and testing various myeloma producing factors (MPFs), such as cytokines, chemokines and growth factors that are important for myeloma cell proliferation and survival. The multiple myeloma cell lines MM1.S, RPMI-8226, and IM9 were tested for their capacity to secrete the full set of 31 cytokines, chemokines and growth factors. RPMI-8226 was selected for MDSA due to its high capacity to secrete MPFs (IL-8, VEGF, MCP-1, MIP-1α, MIP-1β, IP10, RANTES and SIL-6R). RPMI-8226 cells were treated with 10 10−6M of each compound (first screening phase) and 1 10−6M (secondary screening), and supernatants from 72-hour cultures were analyzed. The criterion of effective drugs for each cytokine was set up as the ability to inhibit or stimulate MPFs (exceed +/− 1.5 mean value of non-treated control). The resulting data on the drugs were graded by the degree to which they caused inhibition or stimulation of all MPFs (greater than 50% and greater than 90%). A total of 205 of the 1,120 candidates were picked out from the first screening at 10 10−6M. Results from the second analysis (at 1 10−6M) indicated that 14 compounds achieved inhibition of all MPFs and dequalinium dichloride manifested the strongest inhibition of all MPFs. Forty drugs were able to selectively inhibit certain MPFs at levels that exceeded 50% and 14 drugs inhibited MPFs by 90%. With respect to stimulation of cytokine secretion, a total of 39 compounds demonstrated selective stimulation of some MPFs and three drugs (amethopterin (R, S), etoposide, and lasalocid sodium salt) induced stimulation at the level of 90% or greater. Overall, MDSA is a powerful high throughput screening assay to analyze compounds with inhibitory or stimulatory effects on cytokines, chemokines and growth factors that are involved in the pathogenesis of multiple myeloma. Potent compounds identified in this study warrant further investigation for their anti-myeloma effects in vitro and in vivo.

scholarly journals A new P. falciparum gametocyte drug screening assay based on pLDH detection

2012 ◽  
Vol 11 (S1) ◽  
Author(s):  
Sarah D’Alessandro ◽  
Nicoletta Basilico ◽  
Yolanda Corbett ◽  
Silvia Parapini ◽  
Francesco Silvestrini ◽  
...  
Keyword(s):  
Drug Screening ◽  
Screening Assay ◽  
Drug Screening Assay
Sign in / Sign up

Export Citation Format

Share Document